EMA/PE/0000230373 - paediatric investigation plan

rinatabart sesutecan

Key facts

• Active substance:
  rinatabart sesutecan
• Therapeutic area:
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
• Decision number:
  EMA/PE/0000230373
• PIP number:
  EMA/PE/0000230373
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of fallopian tube cancer
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  28/01/2025
• Compliance check done:
  No

Decision

EMA/PE/0000230373 : EMA decision of 28 January 2025 on the granting of a product specific waiver for rinatabart sesutecan

Adopted Reference Number: EMADOC-1700519818-1840320